The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells

Author(s)
Yokoo, Noritaka; Baba, Shiro; Kaichi, Shinji; Niwa, Akira; Mima, Takahiro; Doi, Hiraku; Yamanaka, Shinya; Nakahata, Tatsutoshi; Heike, Toshio

Citation
Biochemical and Biophysical Research Communications (2009), 387(3): 482-488

Issue Date
2009-09

URL
http://hdl.handle.net/2433/85222

Copyright
This is not the published version. Please cite only the published version.
The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells

Noritaka Yokoo\textsuperscript{a}, Shiro Baba\textsuperscript{a}, Shinji Kaichi\textsuperscript{a}, Akira Niwa\textsuperscript{a}, Takahiro Mima\textsuperscript{a}, Hiraku Doi\textsuperscript{a}, Shinya Yamanaka\textsuperscript{b}, Tatsutoshi Nakahata\textsuperscript{b}, Toshio Heike\textsuperscript{a*}

\textsuperscript{a}Department of Pediatrics, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
\textsuperscript{b}Center for iPS Cell Research and Application (CiRA), Institute for Integrated Cell-Material Sciences, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

\textbf{*Corresponding author}

Name: Toshio Heike MD, PhD
Address: Department of Pediatrics, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Telephone: +81-75-751-3295
Fax: +81-75-752-2361
E-mail: heike@kuhp.kyoto-u.ac.jp
Abstract

Developing effective drug therapies for arrhythmic diseases is hampered by the fact that the same drug can work well in some individuals but not in others. Human induced pluripotent stem (iPS) cells have been vetted as useful tools for drug screening. However, cardioactive drugs have not been shown to have the same effects on iPS cell-derived human cardiomyocytes as on embryonic stem (ES) cell-derived cardiomyocytes or human cardiomyocytes in a clinical setting. Here we show that current cardioactive drugs affect the beating frequency and contractility of iPS cell-derived cardiomyocytes in much the same way as they do ES cell-derived cardiomyocytes, and the results were compatible with empirical results in the clinic. Thus, human iPS cells could become an attractive tool to investigate the effects of cardioactive drugs at the individual level and to screen for individually tailored drugs against cardiac arrhythmic diseases.

Keywords: Human induced pluripotent stem cell, Human embryonic stem cell, Cardiomyocytes, Drug loading test, and Arrhythmia
Introduction

The long-QT syndrome (LQTS) is characterized by an abnormal prolongation of the QT-interval on the ECG and an increased risk of sudden death, due to ventricular fibrillation known as Torsade de Pointes (TdP) [1]. In a previous study [2], four patients died suddenly (1.3% per year) during an average follow-up period of 26 months per patient and among 196 idiopathic LQTS patients, 27 experienced one or more syncopal episodes (8.6% per year). Molecular genetic studies have revealed several forms of congenital LQTS caused by mutations in genes coding for potassium, sodium and calcium channels or membrane adapters [3-6]. Preliminary clinical studies have since suggested the feasibility of performing genotype-specific therapy with therapeutic agents that abbreviate the QT-interval [7]. But it is difficult to select the correct drug because within the same LQTS subtype, the same drug can sometimes have different effects depending on the patient.

Furthermore, the diagnosis of LQTS subtypes is difficult. Genetic testing can only identify 50-75% of probands [8]. So an epinephrine challenge is needed in some patients to diagnose LQTS in a clinical setting [9]. However, this test sometimes induces TdP, so it must be done under careful patient surveillance.

The generation of iPS cells from human fibroblast using a combination of 4 transcription factors (Oct3/4, Sox2, Klf4, and c-Myc) has opened remarkable new avenues for not only basic research but
also regenerative medicine, understanding of disease mechanisms, drug screening, and toxicology [10]. A recent study reported the generation of disease-specific iPS cell lines from patients with a variety of diseases [11]. If patient-specific iPS cells could be commonly generated and employed in a clinical setting, they could become a useful tool for selecting the best drug for individual LQTS patients.

But there has been no report that cardiomyocytes derived from human iPS cells respond to drugs in the same way as human cardiomyocytes. It is important to investigate whether cardiomyocytes derived from human iPS cells react to drugs in the same way as human cardiomyocytes, if patient-specific iPS cells are to be used in a clinical setting for drug screening. Previous studies have hinted that some drugs produce the same effects in cardiomyocytes as in cardiomyocytes derived from ES cells [12-14]. In this study, we investigated whether cardiomyocytes derived human iPS cells responded to drugs in the same way as in cardiomyocytes derived from human ES cells with respect to beating frequency and contractility, and we compared these results with previously described clinical empirical results [15].
Materials and methods

*Human iPS and human ES cell culture.*

We used human ES cell line, KhES1, and human iPS cell lines 201B7. Human iPS cells and human ES cells were maintained on mitomycin-C (Kyowa Hakko) treated mouse embryonic fibroblasts (MEFs) or SNLs on cell culture dishes. In brief, both human iPS and human ES cells were maintained in DMEM/F12 culture medium (SIGMA) supplemented with 20% knock-out serum replacement (Gibco), 0.1 mmol/L nonessential amino acids (Gibco), 4 mmol/L L-glutamine, 0.8 μmol/L basic fibroblast growth factor (bFGF) (Invitrogen).

*Embryoid body formation and cardiac differentiation*

Colonies were detached from cell culture dishes by incubating them with PBS containing 0.25% trypsin (Gibco) and 1 mg/mL collagenase I (Worthington) at 37°C for 3-4 min. The cells were then placed in petri dishes (Sterilin) in suspension cultures for 7 days with maintenance medium supplemented with 5 ng/ml bFGF. Embryoid bodies (EBs) were then plated on 0.1% gelatin-coated 6-well culture plates (BD Biosciences) and cultured in cardiac differentiation medium, consisting of alpha MEM (Gibco) supplemented with 0.5 μmol/L 2ME and 10% FCS (Hyclone) (changed once every 7 days). Contractile colonies appeared 15-25 days after plating on gelatin-coated dishes.
Reverse transcriptase polymerase chain reaction (RT-PCR).

Total RNA was isolated using TRIzol Reagent (Invitrogen) from undifferentiated iPS cells, EBs derived from human iPS cells, the contracting areas of differentiated human iPS cells, and human right ventricular tissue (obtained by a tetralogy of Fallot patient that had received a right flow, ventricular tract ventriculotomy). Total RNA was used for oligo (dT) 12-18-primed reverse transcription using the Super Script II First-Strand Synthesis System (Invitrogen). RT-PCR was carried out using Ex Taq (TAKARA BIO). PCR conditions included denaturation at 94°C for 30 s, annealing at 60°C for 30 s, and extension at 55-65°C for 1 min for 25-35 cycles, with a final extension at 72°C for 7 min. Primers used are listed in Table 3.

Immunohistochemistry

Contractile colonies were partitioned into small particles using collagenase I (Worthington) for 2 h at 37°C. The cells were then washed and plated on 6-well culture plates coated with 0.1% gelatin for 2 or 3 days to allow attachment. Cells were fixed in 4% paraformaldehyde for 15 min at 4°C. Then the cells were incubated with primary antibodies, such as polyclonal anti-cardiac Troponin I (IgG, 1:50 dilution; Santa Cruz Biotechnology), polyclonal anti-MLC2v (IgG, 1:50 dilution; Santa Cruz
Biotechnology), or polyclonal anti-ANP (IgG, 1:250 dilution; Chemicon) in 2% skim milk with 0.1% Triton X-100 overnight at 4°C. Secondary antibodies were cyanine 3 (Cy3)-conjugated donkey anti-rat IgG (1:200 dilution; Jackson Immunoresearch), Cy3-conjugated donkey anti-rabbit IgG (1:200 dilution; Jackson Immunoresearch), and Cy3-conjugated donkey anti-goat IgG (1:200 dilution; Jackson Immunoresearch). Nuclei were counter-stained with Hoechst 33342 (Molecular probes).

Electrophysiological examination

Microelectrode arrays analysis was performed to investigate the electrophysiological potential of cardiomyocytes derived from human iPS cells using the MED 64 system (Alpha MED Sciences) [16-18]. Micro-dissected contracting areas were plated on MED-probe dishes (Alpha MED Sciences) followed by incubation for 3-7 days to allow attachment. The potentials of the contractile colonies derived from these cells were then recorded.

Drug loading test

Differentiation medium was replaced with alpha MEM containing 10 mmol/L HEPES buffer (Nacalai tesque), 7 mol/L NaCl, and 0.5 μmol/L 2ME, which was adjusted to pH 7.4 with NaOH. After 10 min incubation at 37°C, the frequency and contractility of the contractile colonies were
measured in a movie recorded by a VB 7000 (KEYENCE) camera under drug-free medium conditions as well as under drug conditions with three different drug concentrations. Beating colonies were selected when the beating rate was 40/min to 60/min under drug-free medium conditions. Colonies whose contractile motion was distended were excluded. Loading drugs were as follows; isoproterenol (SIGMA), adrenaline (Dai-ichi Sankyo), propranolol (SIGMA), procainamide (Dai-ichi Sankyo), mexiletine (Boehringer Ingelheim), flecainide (Eisai), verapamil (SIGMA), and amiodarone (Sanofi-aventis).

*Analysis of beating rate and contractility*

Beating rates were counted based on the video recordings. Recently, some papers reported that video-edge detecting systems are useful for calculating the contractility of contractile colonies [12]. We imitated this method and calculated the contractility of colonies. In brief, we extracted the still images of systolic phase and diastolic phase from the recorded video images. The major axis of each phase was measured and the contractile index was defined as \( a - b/a \) (\( a \): length of diastolic phase, \( b \): the length of systolic phase) (Fig.4A).

*Statistics*

Data are presented as means ± SEM. Statistical significance was determined by the unpaired \( t \)-test
for two samples and one-way ANOVA followed by the Scheffe test for more than three samples. \( P \) values <0.05 were considered to be statistically significant.
Results

Time course analysis of gene expression during cardiac differentiation

First, we examined the time course of gene expression during cardiac differentiation of human iPS cells by RT-PCR to compare it with that of normal embryogenesis (Fig.1B). Undifferentiated human iPS cells strongly expressed endogenous Oct4 and Sox2, which are undifferentiated cell markers, but did not express the mesodermal marker Brachyury or the cardiac progenitor marker TBX5 (Fig. 1B). KDR was weakly expressed. These results show that undifferentiated human iPS cells have similar properties to undifferentiated human ES cells [19]. Endogenous Oct4 and Sox2 expression gradually decreased during culture in differentiation medium. The expression of the mesodermal marker Brachyury increased from day 10 after EB formation. The expression of KDR also gradually increased from day 10 after EB formation. These patterns of mesodermal marker expression are compatible with those of human ES cells as previously described [19]. The cardiac progenitor marker TBX5 was expressed from day 20 after EB formation, which is compatible with the gene expression patterns seen during cardiac formation in embryogenesis and human ES cell differentiation as previously described [19]. The result additionally suggests that human iPS cells differentiated into the mesodermal lineage and then differentiated into contractile colonies via
cardiac progenitor cells.

*Cardiac differentiation of human iPS cells via EBs*

Next, we examined the contractile colonies consisting of cardiac-specific cells. Contractile colonies were observed from 15 to 25 days after EB formation both in human iPS and human ES cell populations. This result demonstrates that our differentiation methods could generate contractile colonies from both human iPS cells and human ES cells. Next, we investigated whether these contractile colonies were human cardiomyocytes. For this purpose, we carried out RT-PCR and examined for the expression of cardiac cell markers. RT-PCR showed that contractile colonies expressed cardiac markers *Nkx2.5, MEF2c, MLC2a,* and *MYHCB* (Fig. 2A). Moreover, we carried out immunohistochemical analysis to confirm that the contractile colonies were human cardiomyocytes. Contractile colonies were stained by the cardiac cell marker, cTnI, the ventricular cell marker, MLC2v, and the atrial cell marker, ANP. The colonies were also stained by cTnI, and some of them were stained by MLC2v or ANP (Fig. 2C-E). These results of immunohistochemical analysis confirmed that the contractile colonies were indeed human cardiomyocytes.

*Electrical analysis of contractile colonies*

To investigate whether the contractile colonies that expressed cardiac markers were electrically
functional cardiac colonies, we measured their electrical potentials by microelectrode array analysis using the MED 64 system (Alpha MED Sciences) [16-18]. The field potentials of the contractile colonies were comparable to those of cardiomyocytes derived from human ES cells as previously reported (Fig 2F) [16-18]. Moreover, RT-PCR showed that these cells expressed the If channel (HCN4), the L-type calcium channel (CACNA1C), the sodium channel (SCN5A), the inward rectifier (Kir2.1), the transient outward channel (Kv4.3), and the delayed rectifier IKr (HERG) (Fig 2B).

**Effects of drugs on the beating frequency of cardiomyocytes derived from human iPS cells**

We next investigated whether the cardiomyocytes derived from iPS cells reacted with cardioactive drugs in the same manner as cardiomyocytes derived from human ES cells by performing drug loading tests. First we compared the beating frequencies of these two cell populations. A total of eight drugs were tested (see Table 1 for the list of drugs and their concentrations). The β stimulants, adrenaline and isoproterenol increased beating frequency in a dose dependent manner. The beta blocker, propranolol, and the Na channel blockers, procainamide, mexiletine, and flecainide had no effect on beating frequency. The Ca channel blocker verapamil decreased beating frequency in a dose dependent manner, and all contractile colonies ceased to contract when $1 \times 10^{-5}$ M verapamil was loaded. Amiodarone, which mainly acts as a K channel blocker, decreased beating frequency in a dose dependent manner. We carried out β blocker loading in the presence
of $1 \times 10^6$ M isoproterenol in order to mimic conditions in vivo [20]. Under this condition, the beating frequency decreased in a dose dependent manner. There were no statistical differences between the drug concentrations required to elicit the effects in human iPS cells and those required to elicit the effects in cardiomyocytes derived from human ES cells (Fig.3). Previous reports showed that some drugs had similar effects on the beating frequency of cardiomyocytes derived from ES cells and on bone-fide human cardiomyocytes, suggesting that human iPS cells and cardiomyocytes respond similarly to these drugs as well [12-14]. Table 2 shows a comparison of the effects of drug loading on human iPS cells and the effects of these drugs in a clinical setting [15]. As the effects are broadly similar and occur within the same range of drug concentrations, we conclude that cardiomyocytes derived from human iPS cells are a good model for testing the effects of drugs on the beating frequency of human cardiomyocytes. The results are also compatible with previously reported clinical empirical results [15].

The effects of drugs on the contractility of cardiomyocytes derived from human iPS cells

Next, we investigated the effects of drugs on the contractility of human iPS cells and cardiomyocytes derived from human ES cells. The results showed that adrenaline and isoproterenol increased contractility in a dose dependent manner. Propranolol, mexiletine, or amiodarone had no effect on contractility. Verapamil decreased contractility in a dose dependent manner, and all contractile
colonies ceased to contract when $1 \times 10^{-5}$ M verapamil was loaded. Procainamide and flecainide also decreased the beating frequency in a dose dependent manner. We also carried out $\beta$ blocker loading in the presence of $1 \times 10^{-6}$ M isoproterenol with cardiomyocytes derived from human iPS cells, which showed that contractility again decreased in a dose dependent manner under these conditions. There were no statistical differences between the drug concentrations required to elicit the effects in human iPS cells and those required to elicit the effects in cardiomyocytes derived from human ES cells (Fig.4B). Previous reports have shown that some drugs had similar effects on the beating frequency of cardiomyocytes derived from ES cells and on bone-fide human cardiomyocytes, suggesting that human iPS cells and cardiomyocytes respond similarly to these drugs as well [12]. The results were compatible with clinical empirical results [15]. So we conclude that cardiomyocytes derived from human iPS cells respond similarly to drugs that affect contractility in human cardiomyocytes.
Discussion

In this report, we differentiated human iPS cells into cardiomyocytes, and compared the effects of drugs on cardiomyocytes derived from these cells and on cardiomyocytes derived from human ES cells, as well as with empirical results obtained in a clinical setting. The time course analysis of gene expression during cardiac differentiation was compatible to that seen during cardiogenesis of normal embryogenesis, and the results of the drug loading tests showed that cardiomyocytes derived from human iPS cells responded to drugs in much the same way as cardiomyocytes derived from human ES cells. The results were also compatible to empirical results obtained in a clinical setting.

Human iPS cells can be generated from somatic cell by introducing transcriptional factors. This technology is expected to generate patient-specific iPS cells suitable for the study of disease mechanisms, drug screening, and toxicology studies. This technology is easier to implement for the generation of patient-specific pluripotent cells than current technology which relies on nuclear transplantation technology to generate patient-specific pluripotent cells from ES cells. If cardiomyocytes derived from iPS cells could be shown to respond to drugs in the same way as human derived cardiomyocytes, then this technology would also constitute a major advance because it would allow the use of patient-specific iPS cell for the screening of patient-specific drugs against
arrhythmic diseases, especially for lethal arrhythmic diseases such as LQTS where it is often very difficult to select for the best drug.

As the generation of cardiomyocytes from human iPS cells relies on the introduction of exogenous genes, we addressed the troublesome issue of whether cardiomyocytes derived from human iPS cells would respond to drugs in the same way as normal human cardiomyocytes. We considered the beating frequency and contractility to be very important indicators, because heart pump function is defined by beating frequency and contractility. So we investigated the effects of drugs on these two indicators, and found that drugs affect the beating frequency and contractility of cardiomyocytes derived from human iPS cells in much the same way as they do in a clinical setting. This result suggests that cardiomyocytes derived from human iPS cells could be used for drug screening tests instead of current screening procedures in a clinical setting. Cardiomyocytes derived from ES cells also responded to drugs in the same way as cardiomyocytes derived from human iPS cells.

Thus, these results suggest that patient-specific iPS cells could be used to select for the best drug to treat arrhythmic disease at the individual level, and would have the additional advantage of allowing the massive and rapid screening of drugs at concentrations that would be normally prohibitive in patients. However, until further studies are carried out, it is probably still too early to conclude that the drug effects on human iPS cell lines and patients are identical.

In conclusion, cardiomyocytes derived from human iPS cells have tremendous potential for drug
screening, which should open the possibility of using patient-specific iPS cells in a clinical setting.

The best drugs could be selected safely and rapidly by using human iPS cells from individual patients.
**Figure Legends**

Fig. 1 An outline of the protocol used for the differentiation of human iPS cells and human ES cells. Scale bars=200μm (A) Time course analysis of immature gene expression, mesodermal markers, and cardiac progenitor markers during differentiation (B).

Fig. 2 Gene expression analyses of cardiac markers by RT-PCR (A). Gene expression analysis of ion channel related genes (B). Immunohistochemistry of contractile colonies. Colonies were stained with cTnI (C), MLC2v (D), or ANP (E). Scale bars=100μm. Field potentials of contractile colonies measured by the MED 64 system (F).

Fig. 3 The effects of cardioactive drugs on the beating rates of contractile colonies derived from human iPS cells and human ES cells. Adrenaline, isoproterenol, verapamil, amiodarone, and isoproterenol+propranolol had statistically significant effects between pre drug loading and the maximum concentration of the drug used in cardiomyocytes derived from human iPS cells ($P<0.05$). There were no statistically significant differences between the concentrations of drugs that elicited effects in human iPS cells and those that elicited effects in human ES cells.
Fig. 4 Calculation of the contractility index. Right panel; diastolic phase, left panel; systolic phase.

Scale bars=200μm (A). The effect of cardioactive drugs on the contractility of contractile colonies derived from human iPS cells and human ES cells. Adrenaline, isoproterenol, procaineamide, flecainide, verapamil, and isoproterenol+propranolol had statistically significant effects on human iPS cells between pre drug loading and the maximum concentration of the drug used in cardiomyocytes derived from human iPS cells ($P<0.05$). There were no statistically significant differences between the concentrations of drugs that elicited effects in human iPS cells and those that elicited effects in human ES cells (B).
References


<table>
<thead>
<tr>
<th>Class</th>
<th>Drugs</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Na channel blocker</td>
<td>procainamide</td>
<td>$1 \times 10^{-5} \text{ - } 1 \times 10^{-3} \text{ M}$</td>
</tr>
<tr>
<td></td>
<td>mexiletine</td>
<td>$1 \times 10^{-7} \text{ - } 1 \times 10^{-5} \text{ M}$</td>
</tr>
<tr>
<td></td>
<td>flecainide</td>
<td>$1 \times 10^{-7} \text{ - } 1 \times 10^{-5} \text{ M}$</td>
</tr>
<tr>
<td>β blocker</td>
<td>propranolol</td>
<td>$3 \times 10^{-7} \text{ - } 3 \times 10^{-5} \text{ M}$</td>
</tr>
<tr>
<td>K channel blocker</td>
<td>amiodarone</td>
<td>$1 \times 10^{-6} \text{ - } 1 \times 10^{-4} \text{ M}$</td>
</tr>
<tr>
<td>Ca channel blocker</td>
<td>verapamil</td>
<td>$1 \times 10^{-7} \text{ - } 1 \times 10^{-5} \text{ M}$</td>
</tr>
<tr>
<td>α, β stimulant</td>
<td>adrenaline</td>
<td>$5 \times 10^{-7} \text{ - } 5 \times 10^{-5} \text{ M}$</td>
</tr>
<tr>
<td>β stimulant</td>
<td>isoproterenol</td>
<td>$1 \times 10^{-8} \text{ - } 1 \times 10^{-6} \text{ M}$</td>
</tr>
</tbody>
</table>
Table 2: comparison with clinical empirical result

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Result</th>
<th>Clinical efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>contractility</td>
<td>beating frequency</td>
</tr>
<tr>
<td>procainamide</td>
<td>↓</td>
<td>→</td>
</tr>
<tr>
<td>mexiletine</td>
<td>→</td>
<td>→</td>
</tr>
<tr>
<td>flecainide</td>
<td>↓</td>
<td>→</td>
</tr>
<tr>
<td>propranolol</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>amiodarone</td>
<td>→</td>
<td>↓</td>
</tr>
<tr>
<td>verapamil</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>isoproterenol</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>adrenalin</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Genes</td>
<td>Direction</td>
<td>Sequences</td>
</tr>
<tr>
<td>-------------</td>
<td>-----------</td>
<td>------------------------------------</td>
</tr>
<tr>
<td>OCT4 (endo)</td>
<td>Forward</td>
<td>GACAGGGGGAGGGGAGGAGCTAGG</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>CTTCCCTCCCAACCAGTTGCCCCAAAC</td>
</tr>
<tr>
<td>SOX2 (endo)</td>
<td>Forward</td>
<td>GGGAAATGGGGAGGGGTGCAAAGAGG</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>TTGCCTGAGTGTGATGGGATGGGTGGT</td>
</tr>
<tr>
<td>C-KIT</td>
<td>Forward</td>
<td>ATCCCAAGCCCATGAGTCCTTGA</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>ACCACGTGGAACACCAACATCCT</td>
</tr>
<tr>
<td>Brachyury</td>
<td>Forward</td>
<td>AAGGTTGATCTTCAGGTAGC</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>CATCTCATTTGGTGAGCTCC</td>
</tr>
<tr>
<td>KDR</td>
<td>Forward</td>
<td>AAAACCTTTTTGGTCTTTTTGG</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>GAAATGGGGATTGGTAAGGATG</td>
</tr>
<tr>
<td>Nkx2.5</td>
<td>Forward</td>
<td>GCGATTATGAGCGTGCAATGAGT</td>
</tr>
<tr>
<td></td>
<td>Reverse</td>
<td>AACATAAAATACGGGTGGGTGCGTG</td>
</tr>
<tr>
<td>TBX5</td>
<td>Forward</td>
<td>AAAATGAAACCCAGCATAGGAGTGGC</td>
</tr>
<tr>
<td></td>
<td>reverse</td>
<td>ACACGTGGAACCAACATCCTC</td>
</tr>
<tr>
<td>MEF2c</td>
<td>Forward</td>
<td>TTTAACACCAGCCAGCGCTCTTCCACCTTG</td>
</tr>
<tr>
<td></td>
<td>reverse</td>
<td>TCGTGCCGCGGTGTGCTGTGGGTGATCTCC</td>
</tr>
<tr>
<td>MLC2a</td>
<td>Forward</td>
<td>ACATCATCAACCCACCGGAGAGAAGAGA</td>
</tr>
<tr>
<td></td>
<td>reverse</td>
<td>ATTGGAACATGGCCCTCTGGATGGA</td>
</tr>
<tr>
<td>MYHCB</td>
<td>Forward</td>
<td>CTGGGAGGCCAGCAGCAGAAGCAGCGCAACG</td>
</tr>
<tr>
<td></td>
<td>reverse</td>
<td>GTCCGGCCGCTCCTCTGCGCTCTACCTCC</td>
</tr>
<tr>
<td>HCN4</td>
<td>Forward</td>
<td>GGTGTCATCAACAAACATCGG</td>
</tr>
<tr>
<td></td>
<td>reverse</td>
<td>TGTACTGCTCCACCTGCTTG</td>
</tr>
<tr>
<td>SCN5A</td>
<td>Forward</td>
<td>CCTAATCATCTTCCGACATCC</td>
</tr>
<tr>
<td></td>
<td>reverse</td>
<td>TGTTTCATCTCTCTGTCCTCATC</td>
</tr>
<tr>
<td>Kir2.1</td>
<td>Forward</td>
<td>GACCTGGAGACGGACGACGAC</td>
</tr>
<tr>
<td></td>
<td>reverse</td>
<td>AGCCTGGAATCTGCTGCAAAGTC</td>
</tr>
<tr>
<td>Kv4.3</td>
<td>Forward</td>
<td>GCCAGTCCCTGTTGATTGTTT</td>
</tr>
<tr>
<td></td>
<td>reverse</td>
<td>CTCCATGCGAGTTGCTCTCAAA</td>
</tr>
<tr>
<td>HERGY</td>
<td>Forward</td>
<td>TCCAGCGGCTGTACTCGGCGG</td>
</tr>
<tr>
<td></td>
<td>reverse</td>
<td>TGGACCAGAAGTGGTGAGGAACCTC</td>
</tr>
<tr>
<td>CACNA1C</td>
<td>Forward</td>
<td>AACATCAACAAACGCCAAACAA</td>
</tr>
<tr>
<td></td>
<td>reverse</td>
<td>AGGGCAGGACTGCTCTTGGA</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Forward</td>
<td>CACCAGGGGCCTTTTTAACTCTG</td>
</tr>
<tr>
<td></td>
<td>reverse</td>
<td>ATGGTTCAACCCATGCGAAC</td>
</tr>
</tbody>
</table>
Figure 1

A

Suspension culture
bFGF 5ng/ml

Plating EBs on gelatin coated dish

Emergence of beating colonies

0 7 7+15~25

Undifferentiated colony
Embryoid bodies (day7)
Contractile colony

B

Sox2(endo)
OCT4(endo)
Brachyury
KDR
TBX5
GAPDH

water SNL day0 EB day7 7+5 7+10 7+15 7+20
Figure 2

**A**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Water</th>
<th>MEF</th>
<th>iPS cells</th>
<th>Beating coloni</th>
<th>RV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nkx2.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MEF2c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MLC2a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MYHCB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**B**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Water</th>
<th>MEF</th>
<th>Beating coloni</th>
<th>RV</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCN4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCN5A</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kir2.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kv4.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HERG</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CACNA1C</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**C**

- cTnl, DAPI
- MLC2v, DAPI

**D**

- ANP, DAPI

**E**

- 0.2mV, 0.025sec
Figure 3

- **adrenaline**
  - hiPS
  - hES
  - N=5  N=11
  - Pre 0.5 5 50 (μM)

- **isoproterenol**
  - hiPS
  - hES
  - N=8  N=8
  - Pre 0.01 0.1 1 (μM)

- **propranolol**
  - hiPS
  - hES
  - N=5  N=17
  - Pre 0.3 3 30 (μM)

- **procainamide**
  - hiPS
  - hES
  - N=7  N=9
  - Pre 10 100 1000 (μM)

- **mexiletine**
  - hiPS
  - hES
  - N=8  N=9
  - Pre 0.1 1 10 (μM)

- **flecainide**
  - hiPS
  - hES
  - N=11  N=11
  - Pre 0.1 1 10 (μM)

- **verapamil**
  - hiPS
  - hES
  - N=9  N=16
  - Pre 0.1 1 10 (μM)

- **amiodarone**
  - hiPS
  - hES
  - N=6  N=9
  - Pre 1 10 100 (μM)

- **isoproterenol 1μM + propranolol**
  - hiPS
  - hES
  - N=5
  - Pre 0.3 3 30 (μM)
Figure 4

A

Diastolic phase  Systolic phase

Contractility Index = a - b/a

B

<table>
<thead>
<tr>
<th>Adrenaline</th>
<th>Isoproterenol</th>
<th>Propranolol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre 0.5</td>
<td>Pre 0.01</td>
<td>Pre 0.3</td>
</tr>
<tr>
<td>5 50</td>
<td>0.1 1</td>
<td>3 30</td>
</tr>
<tr>
<td>(μM)</td>
<td>(μM)</td>
<td>(μM)</td>
</tr>
<tr>
<td>hiPS N=5</td>
<td>hES N=8</td>
<td>hiPS N=5</td>
</tr>
<tr>
<td>hES N=11</td>
<td>hES N=12</td>
<td>hES N=10</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Procainamide</th>
<th>Mexiletaine</th>
<th>Flecainide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre 10</td>
<td>Pre 0.1</td>
<td>Pre 0.3</td>
</tr>
<tr>
<td>100 1000</td>
<td>1 10</td>
<td>3 30</td>
</tr>
<tr>
<td>(μM)</td>
<td>(μM)</td>
<td>(μM)</td>
</tr>
<tr>
<td>hiPS N=7</td>
<td>hES N=8</td>
<td>hiPS N=6</td>
</tr>
<tr>
<td>hES N=8</td>
<td>hES N=9</td>
<td>hES N=11</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Verapamil</th>
<th>Amiodarone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre 0.1</td>
<td>Pre 0.1</td>
</tr>
<tr>
<td>1 10</td>
<td>1 10</td>
</tr>
<tr>
<td>(μM)</td>
<td>(μM)</td>
</tr>
<tr>
<td>hiPS N=8</td>
<td>hES N=6</td>
</tr>
<tr>
<td>hES N=16</td>
<td>hES N=9</td>
</tr>
</tbody>
</table>

Isoproterenol 1μM + propranolol

Diastolic phase

Systolic phase

Contractility Index = a - b/a